Abstract
We recently defined a high-molecular risk category (HMR) in primary myelofibrosis (PMF), based on the presence of at least one of the five ‘prognostically detrimental’ mutated genes (ASXL1, EZH2, SRSF2 and IDH1/2). Herein, we evaluate the additional prognostic value of the ‘number’ of mutated genes. A total of 797 patients were recruited from Europe (n=537) and the Mayo Clinic (n=260). In the European cohort, 167 (31%) patients were HMR: 127 (23.6%) had one and 40 (7.4%) had two or more mutated genes. The presence of two or more mutations predicted the worst survival: median 2.6 years (hazard ratio (HR) 3.8, 95% confidence interval (CI) 2.6–5.7) vs 7.0 years (HR 1.9, 95% CI 1.4–2.6) for one mutation vs 12.3 years for no mutations. The results were validated in the Mayo cohort and prognostic significance in both cohorts was independent of International Prognostic Scoring System (IPSS; HR 2.4, 95% CI 1.6–3.6) and dynamic IPSS (DIPSS)-plus (HR 1.9, 95% CI 1.2–3.1), respectively. Two or more mutations were also associated with shortened leukemia-free survival (HR 6.2, 95% CI 3.5–10.7), also Mayo validated. Calreticulin mutations favorably affected survival, independently of both number of mutations and IPSS/DIPSS-plus. We conclude that the ‘number’ of prognostically detrimental mutations provides added value in the combined molecular and clinical prognostication of PMF.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Vannucchi AM, Guglielmelli P, Tefferi A . Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin 2009; 59: 171–191.
Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT et al. Improving survival trends in primary myelofibrosis: an International Study. J Clin Oncol 2012; 30: 2981–2987.
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for myelofibrosis research and treatment. Blood 2009; 113: 2895–2901.
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703–1708.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS Plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392–397.
Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A et al. Mutations and prognosis in primary myelofibrosis. Leukemia 2013; 27: 1861–1869.
Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I et al. Impact of mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the COMFORT-II Study. Blood 2014; e-pub ahead of print 23 January 2014 doi:10.1182/blood-2013-11-536557.
Guglielmelli P, Nangalia J, Green AR, Vannucchi AM . CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. Am J Hematol 2014; e-pub ahead of print 24 January 2014 doi:10.1002/ajh.23678.
Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391–2405.
Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379–2390.
Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2013; e-pub ahead of print 26 December 2013 doi:10.1182/blood-2013-11-538983.
Rumi E, Pietra D, Ferretti V, Klampfl T, Harutyunyan AS, Milosevic JD et al. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood 2013; e-pub ahead of print 23 December 2013 doi:10.1182/blood-2013-11-539098.
Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 2014; e-pub ahead of print 9 January 2014 doi:10.1038/leu.2014.3.
Tefferi A, Guglielmelli P, Lasho TL, Rotunno G, Finke C, Mannarelli C et al. CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia 2014; e-pub ahead of print 5 February 2014 doi:10.1038/leu.2014.57.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011; 29: 392–397.
Caramazza D, Begna KH, Gangat N, Vaidya R, Siragusa S, Van Dyke DL et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia 2011; 25: 82–88.
Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010; 116: 2857–2858.
Tefferi A, Pardanani A, Gangat N, Begna KH, Hanson CA, Van Dyke DL et al. Leukemia risk models in primary myelofibrosis: an International Working Group study. Leukemia 2012; 26: 1439–1441.
Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I et al. Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 2014; e-pub ahead of print 29 January 2014 doi:10.1182/blood-2013-11-537167.
Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P et al. Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 2013; 122: 3616–3627.
Acknowledgements
This study was supported by a special grant from Associazione Italiana per la Ricerca sul Cancro-‘AIRC 5 per Mille’- to AGIMM, ‘AIRC-Gruppo Italiano Malattie Mieloproliferative’ (#1005); for a description of the AGIMM project, see at http://www.progettoagimm.it/). The study was partially supported by Ministero della Università e Ricerca (MIUR; FIRB project #RBAP11CZLK and PRIN 2010NYKNS7 to AMV). It was also supported by the Bando ricerca finalizzata e giovani ricercatori, Ministero della Salute GR-2011-02352109 to PG. JS and NCPC were supported by Leukemia and Lymphoma Research. Studies at the Mayo Clinic were supported by the Mayo Clinic Brian and Phyllis Harvey and Janet Yulman Charitable Foundation for Myelofibrosis Tissue Bank and Clinical Database of Molecular and Biological Abnormalities.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Guglielmelli, P., Lasho, T., Rotunno, G. et al. The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia 28, 1804–1810 (2014). https://doi.org/10.1038/leu.2014.76
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2014.76
This article is cited by
-
Clinical characteristics and prognostic significance of DNA methylation regulatory gene mutations in acute myeloid leukemia
Clinical Epigenetics (2023)
-
Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape
Leukemia (2023)
-
Biological drivers of clinical phenotype in myelofibrosis
Leukemia (2023)
-
Phenotypic correlations of CALR mutation variant allele frequency in patients with myelofibrosis
Blood Cancer Journal (2023)
-
High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis
Journal of Applied Genetics (2023)